PharmaShots | Incisive News in 3 Shots

Subscribe Now

CLL

AbbVie Presents Results of Imbruvica (ibrutinib) + Venclexta/Venclyxto in P-III GLOW Study as 1L Treatment for CLL or SLL at EHA 2021

AbbVie Presents Results of Imbruvica (ibrutinib) + Venclexta/Venclyxto in P-III GLOW Study as 1L Treatment for CLL or SLL at EHA 2...

June 14, 2021

Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at ASCO

Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at...

May 20, 2021

Amgen's Riabni (biosimilar- rituximab) Receives the US FDA's Approval for Multiple Diseases

Amgen's Riabni (biosimilar- rituximab) Receives the US FDA's Approval for Multiple Diseases

December 18, 2020

AbbVie Reports Results of Imbruvica (ibrutinib) in Two P-III Studies as 1L Treatment for Chronic Lymphocytic Leukemia

AbbVie Reports Results of Imbruvica (ibrutinib) in Two P-III Studies as 1L Treatment for Chronic Lymphocytic Leukemia

December 8, 2020

AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation to Treat Chronic Lymphocytic Leukaemia (CLL) in Adults

AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation to Treat Chronic Lymphocytic Leukae...

August 14, 2019

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ELEVATE-TN Trial for Patients with Previously Untreated Chronic Lymphocytic Leukemia

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ELEVATE-TN Trial for Patients with Previously Untreated Chronic...

June 6, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us